Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Dynamic monitoring of circulating tumor DNA for real-time risk assessment in early-stage natural killer/t-cell lymphoma

Zegeng Chen, Huang He, Xiaojie Fang, Yuke Tian, Huawei Weng, Liqun Zou, Hongqiang Guo, Hongyu Zhang, Yang Liang, Huangming Hong, Tongyu Lin

Blood (2025) 146 (Supplement 1): 1745.

https://doi.org/10.1182/blood-2025-1745

Published: 2025

Journal Articles

Trial in progress: A phase II, multicentre study to evaluate the efficacy and safety of birelentinib (DZD8586) combination therapy in diffuse large B-cell lymphoma (TAI-SHAN12)

Huiqiang Huang, Wenyu Li, Liqun Zou, Yajun Li, Fang Zhu, Keshu Zhou, Yun Liang, Meifang Zheng, Zengjun Li, Hongmei Jing, Wei Yang, Pengcheng He, Kaiyang Ding, Yuhua Li, Mengling Zhong, Ziyi Liu, Liping Su

Blood (2025) 146 (Supplement 1): 8238.

https://doi.org/10.1182/blood-2025-8238

Published: 2025

Journal Articles

JS203, a CD20×CD3 bispecific antibody, demonstrated promising anti-cancer activity in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL): Updated results from a phase I study

Blood (2025) 146 (Supplement 1): 1957.

https://doi.org/10.1182/blood-2025-1957

Published: 2025

Journal Articles

Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients

Blood (2025) 146 (Supplement 1): 887.

https://doi.org/10.1182/blood-2025-887

Published: 2025

Journal Articles

Polatuzumab vedotin plus R-CHP demonstrates high efficacy with manageable toxicity in treatment-Naïve dual-expressor DLBCL (DEL): Real-world analysis with focus on elderly high-risk patients

Kexing Ren, Liqun Zou, Xi Chen, Ming Jiang, Tian Fang, Li Xie, Beibei Yang, Tao Hai, Chunli Yang, Mo Chen, Yafei Pi

Blood (2025) 146 (Supplement 1): 3698.

https://doi.org/10.1182/blood-2025-3698

Published: 2025

Journal Articles

Mesutoclax (ICP-248) monotherapy or combined with orelabrutinib demonstrates encouraging activity and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Blood (2025) 146 (Supplement 1): 5677.

https://doi.org/10.1182/blood-2025-5677

Published: 2025

Journal Articles

Efficacy and safety of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma: A multicenter, non-interventional, ambispective cohort real-world study

Blood (2025) 146 (Supplement 1): 1878.

https://doi.org/10.1182/blood-2025-1878

Published: 2025

Journal Articles

Glofitamab-based combinatorial therapy demonstrates high efficacy in primary refractory and early relapsed DLBCL: Real-world evidence of durable responses and immune modulation in high-risk subgroups

Kexing Ren, Liqun Zou, Beibei Yang, Ming Jiang, Xi Chen, Li Xie, Chunli Yang, Tao Hai, Mo Chen, Tian Fang, Yafei Pi

Blood (2025) 146 (Supplement 1): 7255.

https://doi.org/10.1182/blood-2025-7255

Published: 2025

Journal Articles

Real-world evidence of improved survival with pola-based regimen in newly diagnosed DLBCL patients with extranodal involvement

Xi Chen, Kexing Ren, Ming Jiang, Liqun Zou

Blood (2025) 146 (Supplement 1): 5472.

https://doi.org/10.1182/blood-2025-5472

Published: 2025

Journal Articles

Linperlisib Combined with CHOP Regimen Followed By Autologous Hematopoietic Stem Cell Transplantation and Linperlisib Monotherapy Maintenance for Newly Diagnosed Nodal T-Follicular Helper Cell Lymphoma Patients: A Phase II Trial

Weiping Liu, Yao Liu, Zengjun Li, Shujuan Wen, Zhihua Zhang, Liqun Zou, Ming Jiang, Liping Dou, Ou Bai, Jie Yu, Yue Wang, Jie Chen, Yuqin Song, Jun Zhu

Blood (2024) 144 (Supplement 1): 6389.

https://doi.org/10.1182/blood-2024-199929

Published: 2024

Journal Articles

The Treatment Pathways, Patient Characteristics and Outcomes in Patients with CD30-Expressing Lymphoma from China: A Multi-Center, Non-Interventional, Retrospective Study

Yi Miao, Wenyu Li, Kaiyang Ding, Fei Li, Xiaojing Yan, Xiaoxi Zhou, Caixia Li, Guohui Cui, Liqun Zou, Bing Xiu, Xiangxiang Zhou, Liansheng Zhang, Fuling Zhou, Hongmei Jing, Jianli Wang, Ziheng Guo, Jianyong Li

Blood (2024) 144 (Supplement 1): 6372.

https://doi.org/10.1182/blood-2024-201339

Published: 2024

Journal Articles

Improving Targeted Therapies in Primary CNS Lymphoma: Real-World Use of Cerebrospinal Fluid Circulating Tumor DNA for Monitoring

Ming Jiang, Liqun Zou, Lijie Liang, Yingze Liu, Na Li, You Feng

Blood (2024) 144 (Supplement 1): 1694.

https://doi.org/10.1182/blood-2024-204947

Published: 2024

Journal Articles

Final Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Zheng Song, Ying Cheng, Haiyan Yang, Liling Zhang, Liqun Zou, Ye Guo, Junning Cao, Huiqiang Huang, Zhao Wang, Sha Huang, Yiqian Fang, Jiaoyan Lyu, Keshu Zhou, Huilai Zhang

Blood (2024) 144 (Supplement 1): 986.

https://doi.org/10.1182/blood-2024-193167

Published: 2024

Journal Articles

Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)

Jie Jin, Liling Zhang, Liqun Zou, Zengjun Li, Huijing Wu, Keshu Zhou, Lihua Qiu, Liping Su, Kaiyang Ding, Hui Zhou, Li Yu, Fei Li, Qing Xiao, Wenyu Li, Lie Lin, Erhua Wang, Lijia Chen, Qingqing Cai

Blood (2024) 144 (Supplement 1): 6368.

https://doi.org/10.1182/blood-2024-211891

Published: 2024

Journal Articles

A Retrospective Analysis of Efficacy and Safety of Orelabrutinib Maintenance in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Zhiming Li, Jun Fang, Huilai Zhang, Wei Wang, Hui Li, Hui Zhou, Liqun Zou, Hong Cen, Wen Shujuan, Wuping Li, Peng Sun, Panpan LIU, Hang Yang, Yu Wang

Blood (2024) 144 (Supplement 1): 6542.

https://doi.org/10.1182/blood-2024-204292

Published: 2024

Journal Articles

Diffuse Large B-Cell Lymphoma Patients with Bone Involvement Treated with Polatuzumab Vedotin-Based Therapy Exhibit Poorer Progression-Free Survival: A Real‐World Retrospective Study in Chinese Patients

Tian Fang, Kexing Ren, Liqun Zou

Blood (2024) 144 (Supplement 1): 7808.

https://doi.org/10.1182/blood-2024-202883

Published: 2024

Journal Articles

Efficacy and Tolerability of Dose-Adjusted Brentuximab Vedotin in Lymphoma: A Chinese Single-Center Retrospective Chart Review Study

Tian Fang, Kexing Ren, Liqun Zou

Blood (2024) 144 (Supplement 1): 7806.

https://doi.org/10.1182/blood-2024-202775

Published: 2024

Journal Articles

Reduction of Radiotherapy Intensity after Achieving Complete Remission with Induction Chemotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma: A Prospective Study

Xi Chen, Li Xie, Ming Jiang, Liqun Zou

Blood (2024) 144 (Supplement 1): 3062.

https://doi.org/10.1182/blood-2024-201965

Published: 2024

Journal Articles

Phase 2 Search Study：XPO1 Inhibitor (ATG-010) Monotherapy in Heavily Pretreated Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Yuqin Song, Qingqing Cai, Qingyuan Zhang, Xiuhua Sun, Haiyan Yang, Zhihua Yao, Liqun Zou, Liling Zhang, Junning Cao, Tingyu Wang, Lanfang Li, Yao Liu, Hongmei Jing, Sujun Gao, Kaiyang Ding, Bingshan Liu, Jun Zhao, Jun Zhu

Blood (2023) 142 (Supplement 1): 6234.

https://doi.org/10.1182/blood-2023-180413

Published: 2023

Journal Articles

A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas

Blood (2023) 142 (Supplement 1): 306.

https://doi.org/10.1182/blood-2023-180137

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Dynamic monitoring of circulating tumor DNA for real-time risk assessment in early-stage natural killer/t-cell lymphoma

Trial in progress: A phase II, multicentre study to evaluate the efficacy and safety of birelentinib (DZD8586) combination therapy in diffuse large B-cell lymphoma (TAI-SHAN12)

JS203, a CD20×CD3 bispecific antibody, demonstrated promising anti-cancer activity in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL): Updated results from a phase I study

Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients

Polatuzumab vedotin plus R-CHP demonstrates high efficacy with manageable toxicity in treatment-Naïve dual-expressor DLBCL (DEL): Real-world analysis with focus on elderly high-risk patients

Mesutoclax (ICP-248) monotherapy or combined with orelabrutinib demonstrates encouraging activity and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Efficacy and safety of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma: A multicenter, non-interventional, ambispective cohort real-world study

Glofitamab-based combinatorial therapy demonstrates high efficacy in primary refractory and early relapsed DLBCL: Real-world evidence of durable responses and immune modulation in high-risk subgroups

Real-world evidence of improved survival with pola-based regimen in newly diagnosed DLBCL patients with extranodal involvement

Linperlisib Combined with CHOP Regimen Followed By Autologous Hematopoietic Stem Cell Transplantation and Linperlisib Monotherapy Maintenance for Newly Diagnosed Nodal T-Follicular Helper Cell Lymphoma Patients: A Phase II Trial

The Treatment Pathways, Patient Characteristics and Outcomes in Patients with CD30-Expressing Lymphoma from China: A Multi-Center, Non-Interventional, Retrospective Study

Improving Targeted Therapies in Primary CNS Lymphoma: Real-World Use of Cerebrospinal Fluid Circulating Tumor DNA for Monitoring

Final Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)

A Retrospective Analysis of Efficacy and Safety of Orelabrutinib Maintenance in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma Patients with Bone Involvement Treated with Polatuzumab Vedotin-Based Therapy Exhibit Poorer Progression-Free Survival: A Real‐World Retrospective Study in Chinese Patients

Efficacy and Tolerability of Dose-Adjusted Brentuximab Vedotin in Lymphoma: A Chinese Single-Center Retrospective Chart Review Study

Reduction of Radiotherapy Intensity after Achieving Complete Remission with Induction Chemotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma: A Prospective Study

Phase 2 Search Study：XPO1 Inhibitor (ATG-010) Monotherapy in Heavily Pretreated Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only